🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesArterial stiffness reduction on GLP-1 — 6 month update

Arterial stiffness reduction on GLP-1 — 6 month update

CarlaRPh_TPA Sat, Dec 28, 2024 at 11:25 PM 15 replies 1,728 viewsPage 1 of 3
This thread is more than 17 months old. Information may be outdated. Consider searching for more recent discussions.
CarlaRPh_TPA
Senior Member
1,890
8,234
Jan 2024
Tampa, FL
Dec 28, 2024 at 11:25 PM#1

Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.

What I am trying to establish is how much of the SELECT benefit is plausibly independent of the weight loss, and whether that distinction changes anything practical.

Numbers rather than impressions, if you have them.

14 17FDA_TrackerJim, ricardo_MIA, BrianDallas92 and 11 others
Reply Quote Save Share Report
PharmacoVig_BOS
Senior Member
1,567
8,901
Feb 2024
Boston, MA
Dec 29, 2024 at 12:40 AM#2
CarlaRPh_TPA said:
Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.
CarlaRPh_TPA said:
...we don't know the long-term effects of cardiovascular risk...

This is a fair point, and I think intellectual honesty requires acknowledging it. GLP-1 agonists in their current form have ~8-10 years of human exposure data. That's not nothing, but it's not 30+ years either.

However: the risk-benefit calculation should also consider the KNOWN long-term effects of untreated obesity — diabetes, cardiovascular disease, cancer, joint destruction, reduced lifespan by 5-10 years.

Uncertainty about GLP-1 long-term safety vs certainty about obesity consequences. The calculus seems clear to me, but reasonable people can disagree.

15 18Dr.GutHealth, amsterdam_pete, LondonLisa and 12 others
Reply Quote Save Share Report
patPC_UT
Member
212
890
Nov 2024
Park City, UT
Dec 29, 2024 at 1:55 AM#3
PharmacoVig_BOS said:
CarlaRPh_TPA said: ...we don't know the long-term effects of cardiovascular risk...

Metabolic syndrome resolution on cardiovascular risk: I went from meeting 5 of 5 diagnostic criteria to meeting ZERO after 13 months of treatment.

The 5 criteria (and my journey):

  1. Waist circumference: 52" → 36" ✅ Resolved
  2. Triglycerides: 254 → 114 ✅ Resolved
  3. HDL: 36 → 56 ✅ Resolved
  4. Blood pressure: 144/96 → 122/76 ✅ Resolved
  5. Fasting glucose: 119 → 88 ✅ Resolved

Metabolic syndrome reversal is, in my view, the most medically significant outcome of GLP-1 therapy.

16 19TomFromTexas, mike.trainer_LA, sarah_nash92 and 13 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
EndoResFellow
Member
456
2,345
Sep 2024
Baltimore, MD
Dec 29, 2024 at 3:10 AM#4
CarlaRPh_TPA said:
Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.

Can confirm. Same sequence, different timescale. Nothing to add that would improve it.

17 20NurseKim_ATL, paul_denver, TinaHashiRN and 14 others
Reply Quote Save Share Report
TinaHashiRN
Member
345
1,567
Sep 2024
Raleigh, NC
Dec 29, 2024 at 10:21 AM#5

Adding the clinical framing, because it changes how the question reads.

Vitamin deficiency cascade with cardiovascular risk: after 6+ months of reduced food intake, I developed a subtle but important pattern: low B12 → elevated homocysteine → increased cardiovascular risk marker.

The connection: B12 is a cofactor for homocysteine metabolism. Without adequate B12, homocysteine accumulates. This is ironic — taking a CV-protective medication while developing a CV risk factor from reduced nutrition.

Solution: comprehensive vitamin supplementation and regular lab monitoring. Don't let the medication's benefits be undermined by nutritional deficiencies.

18 21MikeNYC_runner and 15 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register